Age-related Macular Degeneration Market by Drug Type (Eylea, Lucentis, Beovu), Stage (Intermediate, Early, Late), Route of Administration (Intravitreal, Intravenous), Distribution Channel (Hospital, Specialty Pharmacy) - Global Forecast to 2027
The global Age-related Macular Degeneration market is projected to reach USD ~14 billion by 2027 from ~USD 9 million in 2022, at a CAGR of 9% during the forecast period
To know about the assumptions considered for the study, Request for Free Sample Report
Age-related Macular Degeneration is a common eye disorder occur when a part of the retina called the macula is damaged. This is commonly found in people over age 50 and is the leading cause of severe and permanent vision loss in elderly people. Currently, only a few drugs are approved for the treatment of age-related macular degeneration. However, many companies are developing longer-acting anti-VEGFs and vitreous implants to facilitate sustained delivery of drugs.
Age-related Macular Degeneration Market is expected to grow at a significant growth rate during next five years. The growth of this market is driven by factors such as strong product pipeline, rise in AMD prevalence, increasing burden of retinal disorders, upsurge in the geriatric population, increase in research and development investments, increasing demand for AMD treatment, launches of new products for the treatment of age-related macular degeneration (AMD) and others. However, entry of biosimilars and high adoption of off-label drugs such as Avastin could hinder the market growth.
The Age-related Macular Degeneration market is categorized on the basis of drug type, type, stages, route of administration, distribution channel and region. Based on drug type, age-related macular degeneration market is segmented into Lucentis, Eylea, Avastin, Beovu and others. The report covered age-related macular degeneration market segmentation by type namely, Wet Age-related Macular Degeneration (Wet AMD) and Dry Age-related Macular Degeneration (Dry AMD). On the basis of stages, the age-related macular degeneration market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. On the basis of route of administration, the age-related macular degeneration market is segmented into intravenous route and intravitreal route. Based on the distribution channel, the market is divided into hospital pharmacy, specialty pharmacy and others. Based on the region, the market is divided into North America, Europe, Asia Pacific and Rest of World region.
To know about the assumptions considered for the study, download the pdf brochure
The report is a comprehensive study of current market trends, industry growth drivers, restraints, opportunities and challenges. The exhaustive regional and country level age-related macular degeneration market analysis is provided for 2020-2027. Each market is comprehensively analysed at a granular level to provide in-depth information.
The Age-related Macular Degeneration market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bayer AG (Germany), Pfizer Inc.(US), Bausch Health Companies Inc. (Canada), Regeneron Pharmaceuticals Inc. (US), Amgen Inc. (US), Biogen (US), among others.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
5.12 PIPELINE ANALYSIS
6 AGE-RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 LUCENTIS
6.3 EYLEA
6.4 AVASTIN
6.5 BEOVU
6.6 OTHERS (IF ANY)
7 AGE-RELATED MACULAR DEGENERATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
7.1 INTRODUCTION
7.2 WET AGE–RELATED MACULAR DEGENERATION (WET AMD)
7.3 DRY AGE–RELATED MACULAR DEGENERATION (DRY AMD)
8 AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 EARLY-STAGE AMD
8.3 INTERMEDIATE AMD
8.4 LATE-STAGE AMD
9 AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 INTRAVENOUS ROUTE
9.3 INTRAVITREAL ROUTE
10 AGE-RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
10.1 INTRODUCTION
10.2 HOSPITAL PHARMACY
10.3 SPECIALTY PHARMACY
10.4 OTHERS (IF ANY)
11 AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2020-2027 (USD MILLION)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 ROE
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF APAC
11.5 REST OF THE WORLD (ROW)
11.5.1 LATIN AMERICA
11.5.2 MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
12.4 MARKET SHARE ANALYSIS, 2021
12.5 COMPANY EVALUATION QUADRANT
12.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
12.8 COMPETITIVE SCENARIO
13 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided)*
13.1 F. HOFFMANN-LA ROCHE LTD.
13.2 NOVARTIS AG
13.3 BAYER AG
13.4 PFIZER INC.
13.5 BAUSCH HEALTH COMPANIES INC.
13.6 REGENERON PHARMACEUTICALS INC.
13.7 AMGEN INC.
13.8 BIOGEN
13.9 SAMSUNG BIOEPIS
13.10 PANOPTICA
13.11 AERIE PHARMACEUTICAL INC.
13.12 REGENXBIO INC.
13.13 LINEAGE CELL THERAPEUTICS
13.14 OCUGEN INC.
13.15 CLOVER THERAPEUTICS
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS
14.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in Age-related Macular Degeneration Market